European Commission Approves Neurim Pharmaceuticals’ Slenyto As Treatment For Insomnia Among Children With ADHD

The European Commission approved an expanded treatment indication for Slenyto, a medication developed by Neurim Pharmaceuticals,Ltd., to treat insomnia in children ages 6 to 17 with attention-deficit hyperactivity disorder (ADHD). Slenyto® is a child-appropriate, prolonged-release melatonin formulation. It can be used when sleep hygiene measures have been insufficient.

Slenyto was first approved in the European Union in 2018 for the treatment of insomnia in children ages 2 to 18 with autism spectrum disorder (ASD) and/ or Smith-Magenis Syndrome. In 2024, the indication was extended to children ages 2 to 18 with neurogenetic disorders (NGDs). The . . .